Advertisement

Tumor Biology

, Volume 35, Issue 10, pp 9977–9985 | Cite as

IL-17A G197A and C1249T polymorphisms in gastric carcinogenesis

  • Bing Feng
  • Yonggang Fan
  • Wei Wang
  • Guoliang Yao
  • Jingming Zhai
Research Article

Abstract

Interleukin 17A (IL-17A) is a critical cytokine involved in inflammatory diseases and inflammation-associated cancers. Increasing case-control studies have implicated crucial roles of IL-17A single nucleotide polymorphisms (G197A and C1249T) in gastric carcinogenesis, but providing inconclusive findings. The present study is aimed to estimate the association of IL-17A G197A and C1249T polymorphisms with gastric cancer risk by pooling all available publications. A comprehensive literature search in PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases was performed for eligible publications from their inception up to May 5, 2014. The pooled odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) were calculated to estimate the effect of IL-17A polymorphisms on gastric carcinogenesis. Stratified analysis by ethnicity, Helicobacter pylori (H. pylori) infection, and smoking status were also conducted. All analyses were performed by using the Stata 12.0 software. There were five case-control studies with 2,774 cases and 3,162 controls and two case-control studies with 620 cases and 1,123 controls on the susceptibility of IL-17A G197A and C1249T polymorphisms to gastric cancer, respectively. Significant association was observed between IL-17A G197A polymorphism and gastric cancer risk, particularly among Asians. The status of H. pylori infection and smoking did not influence this association. In addition, the IL-17A C1249T polymorphism did not confer a risk effect on gastric carcinogenesis. The pooled results were not materially altered by sensitivity analysis. We firstly show that the polymorphism of IL-17A G197A but not C1249T is a risk factor for gastric cancer.

Keywords

Interleukin 17A Polymorphism Gastric cancer Meta-analysis 

Notes

Conflicts of interest

None

Funding

This work has no funding to support it.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.CrossRefPubMedGoogle Scholar
  3. 3.
    Qinghai Z, Yanying W, Yunfang C, Xukui Z, Xiaoqiao Z. Effect of interleukin-17A and interleukin-17 F gene polymorphisms on the risk of gastric cancer in a Chinese population. Gene. 2014;537:328–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Su Z, Sun Y, Zhu H, Liu Y, Lin X, Shen H, et al. Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis. Immunol Res. 2014;58:118–24.CrossRefPubMedGoogle Scholar
  5. 5.
    Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M, et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep. 2011;25:1271–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang L, Jiang Y, Zhang Y, Wang Y, Huang S, Wang Z, et al. Association analysis of IL-17A and IL-17 F polymorphisms in Chinese Han women with breast cancer. PLoS One. 2012;7:e34400.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Quan Y, Zhou B, Wang Y, Duan R, Wang K, Gao Q, et al. Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol. 2012;2012:258293.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Zhou B, Zhang P, Wang Y, Shi S, Zhang K, Liao H, et al. Interleukin-17 gene polymorphisms are associated with bladder cancer in a Chinese Han population. Mol Carcinog. 2013;52:871–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  12. 12.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  13. 13.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 470–461.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Rafiei A, Hosseini V, Janbabai G, Ghorbani A, Ajami A, Farzmandfar T, et al. Polymorphism in the interleukin-17A promoter contributes to gastric cancer. World J Gastroenterol. 2013;19:5693–9.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Arisawa T, Tahara T, Shiroeda H, Matsue Y, Minato T, Nomura T, et al. Genetic polymorphisms of IL17A and pri-microRNA-938, targeting IL17A 3′-UTR, influence susceptibility to gastric cancer. Hum Immunol. 2012;73:747–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Wu X, Zeng Z, Chen B, Yu J, Xue L, Hao Y, et al. Association between polymorphisms in interleukin-17A and interleukin-17 F genes and risks of gastric cancer. Int J Cancer. 2010;127:86–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen JJ. Association between IL-23R and IL-17A polymorphisms and gastric cancer susceptibility. Nanjing Med Univer. 2010. [Article in Chinese]Google Scholar
  19. 19.
    Lee SY, Yoon BY, Kim JI, Heo YM, Woo YJ, Park SH, et al. Interleukin-17 increases the expression of Toll-like receptor 3 via the STAT3 pathway in rheumatoid arthritis fibroblast-like synoviocytes. Immunology. 2014;141:353–61.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I, et al. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol. 2014;79:181–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Yazawa T, Shibata M, Gonda K, Machida T, Suzuki S, Kenjo A, et al. Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol. 2013;1:675–9.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Straus DS. TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer. 2013;12:78.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Rokkas T, Sechopoulos P, Pistiolas D, Kothonas F, Margantinis G, Koukoulis G. Population differences concerning TNF-alpha gene polymorphisms in gastric carcinogenesis based on meta-analysis. Ann Gastroenterol. 2014;27:139–48.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Choi IJ. Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med. 2013;28:525–37.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Lee SY. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol. 2012;27:200–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Bornschein J, Malfertheiner P. Helicobacter pylori and gastric cancer. Dig Dis. 2014;32:249–64.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang F, Sun GP, Zou YF, Zhong F, Ma T, Li XQ, et al. Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer. Curr Oncol. 2013;20:e388–395.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, et al. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009;115:2071–80.CrossRefPubMedGoogle Scholar
  30. 30.
    Babhadiashar N, Sotoudeh M, Azizi E, Bashiri J, Didevar R, Malekzadeh R, et al. Correlation between cigarette smoking and urine cotinine level in gastric cancer patients. Iran J Pharm Res. 2014;13:313–8.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Gu J, Zou H, Zheng L, Li X, Chen S, Zhang L. GSTM1 null genotype is associated with increased risk of gastric cancer in both ever-smokers and non-smokers: a meta-analysis of case-control studies. Tumour Biol. 2014;35:3439–45.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Bing Feng
    • 1
  • Yonggang Fan
    • 1
  • Wei Wang
    • 1
  • Guoliang Yao
    • 1
  • Jingming Zhai
    • 1
  1. 1.Department of General SurgeryThe First Affiliated Hospital of Henan Science and Technology UniversityLuoyangChina

Personalised recommendations